Needham analyst Mike Matson maintains ResMed (NYSE:RMD) with a Buy and raises the price target from $224 to $236.
Needham Maintains Buy on ResMed, Raises Price Target to $236
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.